This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

44/100

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Plain-language summary

Objective Hearing loss has been identified as a major modifiable risk factor for cognitive decline. The Early Age-Related Hearing Loss Investigation (EARHLI) study will assess the mechanisms linking early age-related hearing loss (ARHL) and cognitive impairment. Study design Randomized, controlled, single-site, early phase II, superiority trial. Setting Tertiary academic medical center. Participants One hundred fifty participants aged 55 to 75 years with early ARHL (severity defined as borderline to moderate) and amnestic mild cognitive impairment will be included. Interventions Participants will be randomized 1:1 to a best practice hearing intervention or a health education control. Main outcome measures The primary study outcome is cognition measured by the Alzheimer Disease Cooperative Study-Preclinical Alzheimer Cognitive Composite. Secondary outcomes include additional measures of cognition, social engagement, and brain organization/connectivity. Results Trial enrollment will begin in early 2024. Conclusions After its completion in 2028, the EARHLI trial should offer evidence on the effect of hearing treatment versus a health education control on cognitive performance, social engagement, and brain organization/connectivity in 55- to 75-year-old community-dwelling adults with early ARHL and amnestic mild cognitive impairment.

What this study adds

Evidence grade: High

This is a protocol for a trial testing whether hearing treatment affects cognition in people with early age-related hearing loss and mild cognitive impairment. No results are available yet, so no conclusion can be drawn about preventing cognitive decline.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Denham, M. W., Arnold, M. L., Sanchez, V. A., Lin, F. R., Tucker, L. H., Gomez, M. C., et al. (2024). Design and Methods of the Early Age-Related Hearing Loss Investigation Randomized Controlled Trial. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. https://doi.org/10.1097/mao.0000000000004093

Vancouver

Denham MW, Arnold ML, Sanchez VA, Lin FR, Tucker LH, Gomez MC, et al. Design and Methods of the Early Age-Related Hearing Loss Investigation Randomized Controlled Trial. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2024. doi:10.1097/mao.0000000000004093. PMID: 38728564.

BibTeX

@article{denham2024-38728564,
  author  = {Denham, M. W. and Arnold, M. L. and Sanchez, V. A. and Lin, F. R. and Tucker, L. H. and Gomez, M. C. and Fernandez, K. and Arpi, P. and others},
  title   = {{Design and Methods of the Early Age-Related Hearing Loss Investigation Randomized Controlled Trial}},
  journal = {Otology \& neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology},
  year    = {2024},
  doi     = {10.1097/mao.0000000000004093},
  pmid    = {38728564},
  url     = {https://doi.org/10.1097/mao.0000000000004093}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded high. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. High means the abstract mentions a randomized design, a meta-analysis or a systematic review. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Results Trial enrollment will begin in early 2024.
Conclusions After its completion in 2028, the EARHLI trial should offer evidence on the effect of hearing treatment versus a health education control on cognitive performance, social engagement, and brain organization/connectivity in 55- to 75-year-old community-dwelling adults with early ARHL and amnestic mild cognitive impairment.

Why it matters

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthHigh

How this study scored 44/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology)
Journal's citation record	1 / 4	Otology & Neurotology: journal h-index 142 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	1 / 2	Randomized (as stated in the record)
Times cited	2 / 7	Cited 8 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.0 citations a year over 4 year(s) since 2024
Impact for its field and year	2 / 6	Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	1 / 4	Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Justin S. Golub: h-index 34 (OpenAlex, whole career)
Institution's track record	3 / 3	University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 8 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 38728564)
Free to read	0 / 2	Behind a paywall — scores zero
Total	44 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Treatments from nearby years

Also in Treatments

196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →